Evidence map›Paper›PMID 41708064›Full record

ArticleACS applied bio materials2026

Decellularized Dermis ECM-Based Melanoma-on-a-Chip Model with Integrated Lymphatic and Vascular Networks for High-Throughput Drug Testing.

Paula Vázquez-Aristizabal, Inazio Arriola-Alvarez, Malou Henriksen-Lacey, Sonia Alonso-Martin, Lenie van den Broek, Luis M Liz-Marzán, Ander Izeta

Abstract read
In one paragraph

Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paula Vázquez-AristizabalCIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastián, Spain.
Inazio Arriola-AlvarezBiogipuzkoa Health Research Institute, Stem Cells & Aging Group, 20014 Donostia-San Sebastián, Spain.
Malou Henriksen-LaceyCIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastián, Spain.ORCID 0000-0003-3544-5846
Sonia Alonso-MartinBiogipuzkoa Health Research Institute, Stem Cells & Aging Group, 20014 Donostia-San Sebastián, Spain.ORCID 0000-0002-3254-0365
Lenie van den BroekMimetas BV, De Limes 7, 2342DH Oegstgeest, The Netherlands.
Luis M Liz-MarzánCIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastián, Spain.ORCID 0000-0002-6647-1353
Ander IzetaBiogipuzkoa Health Research Institute, Stem Cells & Aging Group, 20014 Donostia-San Sebastián, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing effective treatments for malignant melanoma remains a complex challenge, requiring models that accurately replicate the tumor microenvironment to study metastasis and drug response. Whereas

Indexed as

Antineoplastic AgentsBiocompatible MaterialsDermisExtracellular MatrixHigh-Throughput Screening AssaysLab-On-A-Chip DevicesMelanomaDrug Screening Assays, AntitumorHumansLymphatic VesselsMaterials TestingMicrophysiological SystemsTumor MicroenvironmentAntineoplastic AgentsBiocompatible MaterialsdECMdrug testinglymphaticmelanomamicrofluidicvascularization

Identifiers

PMID41708064
PMCPMC12997241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.